Lonza Group AG announced that after seven years as board member and six years as Chairman of Lonza, Albert Baehny has decided to not stand for re-election at the upcoming annual general meeting (AGM) in May 2024. The board of directors recognizes the instrumental role of Albert Baehny during his tenure, including leading the company as CEO ad interim during the pandemic and in the current transition to a new CEO. The board will propose to shareholders at the 2024 AGM the election of Jean-Marc Huët as the new Chairman of the Board.

To ensure continuity and a seamless transition, Albert Baehny will remain CEO ad interim of Lonza until the new CEO commences their tenure. Albert Baehny joined the Board of Lonza in 2017 and assumed the role of Chairman in 2018. He steered the company through the pandemic, securing Lonza?s prominent role in contributing to the fight against the COVID-19 pandemic.

During his tenure, the company transformed from a chemical and pharma conglomerate to one of the larger healthcare manufacturing organizations, serving the pharmaceutical, biotech and nutrition markets.